Novo Nordisk to Establish Insulin Production in South Africa
By Dominic Chopping
Novo Nordisk aims to produce insulin in South Africa along with a partner to treat diabetics across the African continent, it said on Tuesday.
The Danish pharmaceutical giant said it will work with Aspen SA Operations and Aspen Pharmacare in South Africa to produce 16 million vials next year which could treat 1.1 million people annually.
By 2026, Novo Nordisk plans to treat 4.1 million people living with type 1 and type 2 diabetes across the African continent.
The insulin will be distributed at low-cost to health authorities and non-governmental organisations through government tenders and the company said it will guarantee a ceiling price of $3 per vial.
Around 24 million adults currently live with diabetes in Africa and this figure is estimated to increase to 55 million by 2045, it said.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 19, 2023 07:10 ET (11:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
What the Fed’s QT Program Is, and Why Its End Matters
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?